Taiho Oncology, Inc.
Mehul Jhonsa has extensive work experience in the pharmaceutical industry. Mehul started working at Daiichi Sankyo, Inc. in 2012, where they held the position of Manager. Mehul then joined Valeant Pharmaceuticals in 2013 as a Pharmacovigilance Senior Manager. In 2017, Mehul transitioned to Taiho Oncology, Inc., where they took on progressively senior roles. Mehul started as an Associate Director of Pharmacovigilance, Vendor Oversight & Business Integration, then became a Director in the same department, and eventually achieved the position of Senior Director. Mehul is currently responsible for pharmacovigilance, vendor oversight, and business integration at Taiho Oncology, Inc.
Mehul Jhonsa attended Rutgers University from 1996 to 2002, where they pursued a Doctor of Pharmacy (Pharm.D.) degree with a focus on Pharmacy.
This person is not in any teams
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com